Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »

Doctors reliance on pharmas increasing, while general public trusts supermarkets more. What’s wrong with this picture?

The News: When it comes to pharma partners, doctors prefer quality digital content, according to a new report. While that comes as no surprise and makes sense, new research shows… Read more »

First FDA-approved gene-therapy procedure for inherited blindness performed in US. Advance is fantastic news, but same quandary: Who can afford it?

The News: Massachusetts Eye and Ear, a Harvard teaching hospital based in Boston, recently became the first institution to treat a patient’s inherited retinal disorder with gene therapy. The patient,… Read more »

Insys attempting “Phoenix” impersonation as key Q1 earnings slated for Tuesday. Analysts say Buy, but is now the time?

The News: A former Insys Therapeutics Inc. (Chandler AZ) sales representative was recently sentenced to six months of home confinement after admitting that she participated in a scheme to pay… Read more »

Biotech IPO tsunami continues even as stocks sag following FDA chief’s drug-price rant.

The News: US Food and Drug Administration chief Scott Gottlieb on Thursday (May 3, 2018) questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law,… Read more »

Boomer Alert: Aging immune cells increase risk for macular degeneration, blindness. Apellis, Ophthotech to the rescue?

The News: As people age, so do their immune systems. And new research at Washington University School of Medicine in St. Louis suggests that aging immune cells increase the risk… Read more »

Innovent Biologics epitomizes how China, not Russia, quickly becoming real threat to US biotech supremacy.

The News: China’s Innovent Biologics Inc. has raised $150 million in a Series E crossover round, with Capital Group Private Markets picking up $90 million of the mega-round, according to Endpoints. The… Read more »

Apitope moves Graves’ disease candidate toward Phase 2; a primer on autoimmune disease “for people in a hurry.”

The News: Apitope International NV has taken a step closer to developing the first new treatment option in decades for thyroid disorder Graves’ disease after posting positive results in a… Read more »

Elizabeth Holmes and Mark Zuckerberg: The rise and fall of the black turtleneck, hoodie and jeans. Op Ed

While scanning the healthcare news yesterday I was struck, perhaps a bit startled even, by a video clip of Facebook CEO Mark Zuckerberg, clad in a dark suit and tie and… Read more »